RARE DISEASE COMPANY COALITION

Lobbying for RARE DISEASE COMPANY COALITION · Healthcare

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 18, 2025

Expenses

$70,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 4

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
SENATE
U.S. Trade Representative (USTR)

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 4

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 1262
Mikaela Naylon Give Kids a Chance Act
HR 946
ORPHAN Cures Act
HR 1414
Cameron’s Law

Lobbying activity 4

Budget/Appropriations

HR 1 - Big Beautiful Bill Act

Pharmacy

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities

Science/Technology

Executive Order 14297 - Impact of EO on Rare Disease Innovation Rare Disease Policy

Trade (domestic/foreign)

Sec. 232 Pharmaceutical Tariffs

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.